Here is the point: Where there is a lower baseline risk, like risk of hospitalization or death in patients with covid, the higher sample size you need to have reasonable statistical power. If the baseline risk is higher, as it is with ventilated ARDS patients, you can have that statistical power with a smaller sample size.
- Forums
- ASX - By Stock
- MSB
- New Covid 19 treatment
New Covid 19 treatment, page-301
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B |
Open | High | Low | Value | Volume |
$1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 29972 | $1.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 2008 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 29972 | 1.305 |
4 | 15000 | 1.300 |
6 | 89978 | 1.295 |
10 | 88399 | 1.290 |
3 | 86112 | 1.285 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 2008 | 1 |
1.315 | 12924 | 1 |
1.320 | 30099 | 5 |
1.325 | 32683 | 3 |
1.330 | 20707 | 3 |
Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |